 |
인쇄하기
취소
|
Schnell to conduct Phase I trial for biosimilar drug
Schnell Biopharmaceutical said it will carry out its Phase 1 clinical trial for its arthritis biosimilar after recent approval from the Korea Food and Drug Administration.
Schnell plans to develop and commercialize the drug candidate named GS 071 together with Japan’s Nichi-Iko Pharmaceuticals.
GS 071 is a biosimilar version of Remicade, a blockbuster treatment sold by a U.S. pharmaceutic...
Schnell plans to develop and commercialize the drug candidate named GS 071 together with Japan’s Nichi-Iko Pharmaceuticals.
GS 071 is a biosimilar version of Remicade, a blockbuster treatment sold by a U.S. pharmaceutic...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.